Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream

Vito Di Lernia, C. Ricci, G. Albertini

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. Recently, many clinical trials highlighted the potential of imiquimod as a treatment for other viral infections and cutaneous neoplasms. We report two cases of facial keratoacanthomas (KA) treated with topical 5% imiquimod cream. Patients were successfully cleared of KAs after treatment for 8 weeks. No recurrence occurred after a 1 -year follow-up. Despite the fact that KAs are characterized by the potential for spontaneous regression, it is possible that a faster activation of CD4+ lymphocytes, via interferon release and cytokine secretion takes place after imiquimod application leading to KA regression.

Original languageEnglish
Pages (from-to)626-629
Number of pages4
JournalJournal of the European Academy of Dermatology and Venereology
Volume18
Issue number5
DOIs
Publication statusPublished - Sep 2004

Fingerprint

imiquimod
Keratoacanthoma
Condylomata Acuminata
Skin Neoplasms
Virus Diseases
Therapeutics
Lymphocyte Activation
Interferons
Clinical Trials
Cytokines
Recurrence

Keywords

  • Imiquimod
  • Interferon
  • Keratoacanthoma
  • Tumour

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

@article{6939da594a4d4876ad445d1ab0865e72,
title = "Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream",
abstract = "Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. Recently, many clinical trials highlighted the potential of imiquimod as a treatment for other viral infections and cutaneous neoplasms. We report two cases of facial keratoacanthomas (KA) treated with topical 5{\%} imiquimod cream. Patients were successfully cleared of KAs after treatment for 8 weeks. No recurrence occurred after a 1 -year follow-up. Despite the fact that KAs are characterized by the potential for spontaneous regression, it is possible that a faster activation of CD4+ lymphocytes, via interferon release and cytokine secretion takes place after imiquimod application leading to KA regression.",
keywords = "Imiquimod, Interferon, Keratoacanthoma, Tumour",
author = "{Di Lernia}, Vito and C. Ricci and G. Albertini",
year = "2004",
month = "9",
doi = "10.1111/j.1468-3083.2004.01025.x",
language = "English",
volume = "18",
pages = "626--629",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "5",

}

TY - JOUR

T1 - Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream

AU - Di Lernia, Vito

AU - Ricci, C.

AU - Albertini, G.

PY - 2004/9

Y1 - 2004/9

N2 - Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. Recently, many clinical trials highlighted the potential of imiquimod as a treatment for other viral infections and cutaneous neoplasms. We report two cases of facial keratoacanthomas (KA) treated with topical 5% imiquimod cream. Patients were successfully cleared of KAs after treatment for 8 weeks. No recurrence occurred after a 1 -year follow-up. Despite the fact that KAs are characterized by the potential for spontaneous regression, it is possible that a faster activation of CD4+ lymphocytes, via interferon release and cytokine secretion takes place after imiquimod application leading to KA regression.

AB - Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. Recently, many clinical trials highlighted the potential of imiquimod as a treatment for other viral infections and cutaneous neoplasms. We report two cases of facial keratoacanthomas (KA) treated with topical 5% imiquimod cream. Patients were successfully cleared of KAs after treatment for 8 weeks. No recurrence occurred after a 1 -year follow-up. Despite the fact that KAs are characterized by the potential for spontaneous regression, it is possible that a faster activation of CD4+ lymphocytes, via interferon release and cytokine secretion takes place after imiquimod application leading to KA regression.

KW - Imiquimod

KW - Interferon

KW - Keratoacanthoma

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=4544311618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544311618&partnerID=8YFLogxK

U2 - 10.1111/j.1468-3083.2004.01025.x

DO - 10.1111/j.1468-3083.2004.01025.x

M3 - Article

C2 - 15324413

AN - SCOPUS:4544311618

VL - 18

SP - 626

EP - 629

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 5

ER -